June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Efficacy of an IL-6R antibody in a novel murine dry eye model
Author Affiliations & Notes
  • Adrianna Latuszek
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • Ming Yuan
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • Ying Hu
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • George D. Yancopoulos
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • Stanley J Wiegand
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • Jingtai Cao
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • Carl Romano
    Ophthalmology, Regeneron Pharmaceuticals, Tarrytown, NY
  • Footnotes
    Commercial Relationships Adrianna Latuszek, Regeneron Pharmaceuticals (E); Ming Yuan, Regeneron Pharmaceuticals (E); Ying Hu, Regeneron Pharmaceuticals (E); George Yancopoulos, Regeneron Pharmaceuticals (E); Stanley Wiegand, Regeneron Pharmaceuticals (E); Jingtai Cao, Regeneron Pharmaceuticals (E); Carl Romano, Regeneron Pharmaceuticals (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4491. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Adrianna Latuszek, Ming Yuan, Ying Hu, George D. Yancopoulos, Stanley J Wiegand, Jingtai Cao, Carl Romano; Efficacy of an IL-6R antibody in a novel murine dry eye model. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4491. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The aim of the present study was to develop a clinically relevant mouse dry eye model, combining aqueous tear deficiency and local cornea inflammation. Furthermore, we evaluated the efficacy of an antibody (Ab) directed towards mouse IL-6R in this model.

Methods: For model development, adult, male C57BL/6 mice (Taconic labs) were randomized to naive, sham, benzalkonium chloride (BAC), scopolamine (SCOP) or BAC plus SCOP groups. For SCOP, mice were subcutaneously implanted with osmotic mini-pump filled with SCOP (delivering 2mg/20g B.W./day) lasting for 4 weeks. For BAC, 1ul 0.2% BAC was administered topically to the right eye, B.I.D, 2 days/week. For Ab treatment, mice received BAC plus SCOP, and either anti-mIL6R (10, 35 or 100 mg/kg) or mouse IgG2a Fc control (mFc, 33.3mg/kg) subcutaneously administered twice/week for 4 weeks. Tear production and corneal fluorescein staining were measured every week. On day 28, animals were euthanized. Corneal angiogenesis and lymphangiogenesis were also quantified.

Results: BAC plus SCOP provided a robust dry eye syndrome. Tear production was inhibited by more than 50% (in both SCOP groups, as expected). Corneal fluorescein staining was significantly increased compared to other groups (p<0.001). Corneal angiogenesis and lymphangiogenesis were also significantly increased in this dry eye model. Interestingly, lymphangiogensis but not angiogenesis was significantly correlated with corneal fluorescein staining (p<0.01). We then evaluated the effect of an antibody to IL-6R in this model. Anti-IL-6R treatment has no significant effect on body weight or tear production. However, compared with mFc, anti-IL-6R treatment dose-dependently and significantly decreased both corneal fluorescein staining (30% reduction with 100mg/kg) and associated lymphangiogenesis (50% reduction with 100mg/kg) at 4 weeks.

Conclusions: We have established a novel dry eye model with reduced tear secretion and enhanced damage, angiogenesis, and lymphangiogenesis in cornea. Systemic administration of IL-6R antibody alleviated the corneal damage. Anti-IL-6R treatment is a potential therapeutic strategy in dry eye disease.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×